WuXi AppTec

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Retrieved on: 
Tuesday, February 27, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Shift, Wuxi, Doctor of Philosophy, WuXi AppTec, MD, Risk, Conference, Unit, Cerebral edema, Biomarker, Patient, Drug, NDA, DSM-IV codes

“The new treatment landscape for Alzheimer’s disease is beginning to take shape, and Alzheon’s simplified approach has an opportunity to transform the standard of care and improve access to treatment for Alzheimer’s patients.

Key Points: 
  • “The new treatment landscape for Alzheimer’s disease is beginning to take shape, and Alzheon’s simplified approach has an opportunity to transform the standard of care and improve access to treatment for Alzheimer’s patients.
  • ALZ-801’s efficacy data and favorable safety profile, showing no increased risk of vasogenic edema, underscore the differentiated clinical profile of our treatment,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • Results from our pivotal APOLLOE4 Phase 3 trial will set the stage for the potential NDA filing this year and commercial launch in 2025.”
    Alzheon presentations include two posters and two symposium presentations.
  • If the results of our study are positive, we will be moving quickly to bring an oral option to Alzheimer’s patients and their families,” said John Hey, PhD, Chief Scientific Officer.

Global Genome Editing Market Research Report 2023-2035: Pharmaceutical Giants Expand Capabilities - WuXi AppTec and Ensoma Lead Acquisitions - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Health, Genetics, Acquisition, Wuxi, Regenerative medicine, CRISPR, WuXi AppTec, Gene editing, Intellia Therapeutics, Research, Cas9, Drug discovery, Mammoth Biosciences, Genetic engineering, Safety, Therapy, Genome, Horizon Discovery, Genomics, Antibiotics

The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).

Genome Editing Market Report 2024: Technology Licensing Deals are Driving the Overall Partnership Activity - Global Industry Trends and Forecasts 2023-2035

Retrieved on: 
Wednesday, February 7, 2024
Genomics, Genetic engineering, Mammoth Biosciences, Regenerative medicine, Gene editing, Research, Horizon Discovery, Safety, Wuxi, Drug discovery, Intellia Therapeutics, Therapy, Acquisition, Cas9, CRISPR, WuXi AppTec, Genome, Antibiotics

DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

Retrieved on: 
Monday, January 8, 2024
Marketing, Associate, PEGylation, Commercial, Biotechnology, Spacecraft, Pennsylvania State University, Quality management system, Binghamton University, Ania, Control, Technology transfer, Annual report, Robert Morris University, CMC, Lehigh University, University, Region, Doctor of Philosophy, Therapy, Scorpius, PPQ, Patheon, Chemical engineering, Rutgers University, Computer science, Biochemical engineering, Research, GMP, WuXi AppTec, Business development, Quality assurance, Growth, Investment, Bristol Myers Squibb

The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.

Key Points: 
  • The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.
  • Jeff Wolf, CEO of Nighthawk, commented, “Our rebranding to Scorpius Holdings is a testament to our successful transition and the growth of our CDMO operations.
  • The industry faces a critical shortage of clinical-scale biologic manufacturing capacity, driven by increasing demand for large molecule CDMO services.
  • Our state-of-the-art facility in San Antonio, Texas ideally positions us to address this gap in CDMO manufacturing capacity and services.

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan

Retrieved on: 
Thursday, November 9, 2023
Eye, Quality of life, WuXi AppTec, Wuxi, Growth, Development, Patient, Frost, Drug discovery, Automotive Executive of the Year Award, Fine chemical

SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, received the 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a growth advisory & growth opportunity analytics firm.

Key Points: 
  • SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, received the 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a growth advisory & growth opportunity analytics firm.
  • "We are honored to receive the 2023 Company of the Year Award from Frost & Sullivan," said Dr. Ge Li, Chairman and CEO of WuXi AppTec.
  • "Through its CRDMO and CTDMO business models, WuXi AppTec facilitates the seamless integration of drug discovery, development, and manufacturing processes."
  • This marks the seventh consecutive year that WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.

Novotech Announces Key Leadership Appointments: Rick Farris, North America Managing Director and Dr. David Ng, Global Vice President of Biometrics and Data

Retrieved on: 
Friday, October 13, 2023
Partnership, WuXi AppTec, Drug development, IQVIA, Data management, Growth, Biometrics, Biostatistics, Automotive Executive of the Year Award, Rare, PPD, History, ChromeOS, Thermo Fisher Scientific, Wuxi, Ng, Fine chemical, Nursing, Management

Dr. David Ng a specialist in biostatistics and biometrics has assumed the position of Global Vice President for Biometrics and Data Management.

Key Points: 
  • Dr. David Ng a specialist in biostatistics and biometrics has assumed the position of Global Vice President for Biometrics and Data Management.
  • “Rick has led operations teams and played a key role in establishing global project management capabilities.
  • I am joining at an exciting time, where Novotech is further expanding the North America operations to serve the innovative biotech market,” commented Rick.
  • Dr. David Ng’s appointment as Novotech’s Global VP of Biometrics and Data Management brings over three decades of biostatistics, data management, and strategic leadership.

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

Retrieved on: 
Tuesday, May 2, 2023
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, WuXi AppTec, Immortalised cell line, Antler, Sphere Fluidics, SOCOM II U.S. Navy SEALs, Financial services, Face, TMT, Goldman Sachs, M&A, WuXi Biologics, Acquisition, HH, Thunderbird School of Global Management, Trade sale, NYSE, BA, Pharmaceutical industry, Health care

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.

Key Points: 
  • Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.
  • With over 30 years in the healthcare industry, Ken brings extensive strategic advisory, M&A, underwriting and other transactional expertise.
  • Kenneth Hitchner, Chairman of Board of Directors, Sphere Fluidics, commented: “Sphere Fluidics is changing the face of cell line development.
  • This expertise will help us in our future plans for building business value and ultimately exiting via a Trade Sale or IPO.”
    For more information about Sphere Fluidics, please visit: https://spherefluidics.com/

Forge Biologics Deepens Genetic Medicine CDMO Capabilities with Leadership Team Expansion Across cGMP Manufacturing, Analytical Development, and Client Development

Retrieved on: 
Wednesday, January 25, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Validation, Nationwide, AAV, Novartis, Government, Keck School of Medicine of USC, Technology transfer, Biochemistry, Barkey, Gene, University, Business development, Greiner, Senior, Cell, Therapy, Epidemiology, Samsung Biologics, Ohio State University, Growth, Bioreactor, WuXi AppTec, Problem solving, Multimedia, BioMarin Pharmaceutical, Environment, Pennsylvania State University, Consultant, Fine chemical, Vaccine, Forge, Chemistry

Prior to joining Forge, Mr. McPherson helped to scale processes and complete the technology transfer from 20L to 15,000L of biologics manufacturing.

Key Points: 
  • Prior to joining Forge, Mr. McPherson helped to scale processes and complete the technology transfer from 20L to 15,000L of biologics manufacturing.
  • Taleen Barsoumian will lead Forge’s client development strategy and new business operations across Forge’s suite of manufacturing solutions.
  • Adam Davis leads the in-house analytical development and testing team supporting clients throughout product development and manufacturing.
  • Dr. Davis joined Forge in 2020 after 15 years of experience in recombinant adeno-associated viral (AAV) vector product development, process development, and manufacturing.

WuXi AppTec Named "Industry Mover" in S&P Global Sustainability Yearbook 2023

Retrieved on: 
Thursday, February 16, 2023
Sustainalytics, CSA, WuXi AppTec, Patient, Yearbook, ESG, MSCI, Social, AA, Wuxi, Fine chemical, Renewable energy, Biophysical environment

WuXi AppTec is the only company to be named as "Industry Mover" this year from the Life Science Tools & Services industry.

Key Points: 
  • WuXi AppTec is the only company to be named as "Industry Mover" this year from the Life Science Tools & Services industry.
  • The S&P Global Sustainability Yearbook aims to distinguish companies that have demonstrated strengths in corporate sustainability.
  • The recognition of WuXi AppTec as an "Industry Mover" demonstrates WuXi AppTec's strong performance and commitment to Environmental, Social and Governance (ESG) initiatives.
  • "WuXi AppTec remains steadfast in its commitment to customers, investors, employees, patients, and other stakeholders to operate in a sustainable way," said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec's ESG Committee.

Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully

Retrieved on: 
Monday, August 15, 2022
ChiNext, Industry, R, CRO, Clinical trial, VC, Data management, ESG, WuXi AppTec, WuXi Biologics, D, RMB, Health, Series, UNPRI, Shenzhen Stock Exchange, USD, Fine chemical, Bellen

HONG KONG, Aug 15, 2022 - (ACN Newswire) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange.

Key Points: 
  • HONG KONG, Aug 15, 2022 - (ACN Newswire) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange.
  • Legend Capital invested in the Series A round of R&G PharmaStudies in the second half of 2017 and has kept on supporting the development of R&G PharmaStudies.
  • Jafar Wang, the Co-Chief Investment Officer of Legend Capital, said, "Congratulations on the successful listing of R&G PharmaStudies!
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.